How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14332 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Dionysios Neofytos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Transplant Unit, University Hospitals of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, COVID-19, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Among immunocompromised hosts, leukemia patients, and hematopoietic cell transplant recipients are particularly vulnerable, facing challenges in balancing coronavirus disease 2019 (COVID‐19) management with their underlying conditions. In this How I Treat article, we discuss how we approach severe acute respiratory syndrome coronavirus 2 infections in daily clinical practice, considering the existing body of literature and for topics where the available data are not sufficient to provide adequate guidance, we provide our opinion based on our clinical expertise and experience. Diagnostic approaches include nasopharyngeal swabs for polymerase chain reaction testing and chest computed tomography scans for symptomatic patients at risk of disease progression. Preventive measures involve strict infection control protocols and prioritizing vaccination for both patients and their families. Decisions regarding chemotherapy or hematopoietic cell transplantation in leukemia patients with COVID‐19 require careful consideration of factors such as COVID‐19 severity and treatment urgency. Treatment protocols include early initiation of antiviral therapy, with nirmatrelvir/ritonavir or remdesivir. For cases of prolonged viral shedding, distinguishing between viable and non‐viable viruses remains challenging but is crucial for determining contagiousness and guiding management decisions. Overall, individualized approaches considering immune status, clinical presentation, and viral kinetics are essential for effectively managing COVID‐19 in leukemia patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Transplant Unit, University Hospitals of Geneva, Geneva, Switzerland.
- Departments of Biomedicine and Clinical Research, Division of Infectious Diseases, University and University Hospital of Basel, Basel, Switzerland.
ORCID-Profile: Dionysios Neofytos, Nina Khanna
Zitieren
APA
Neofytos, D., & Khanna, N. (2024). How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14332
Vancouver
Neofytos D, Khanna N. How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients. Transplant Infectious Disease. 2024. doi:10.1111/tid.14332
BibTeX
@article{Neofytos2024,
author = {Neofytos, Dionysios and Khanna, Nina},
title = {How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14332}
}
EUVIMED